Second-line systemic treatment for advanced cholangiocarcinoma
about
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Promising therapeutics of gastrointestinal cancers in clinical trials.The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis.Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.
P2860
Second-line systemic treatment for advanced cholangiocarcinoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Second-line systemic treatment for advanced cholangiocarcinoma
@ast
Second-line systemic treatment for advanced cholangiocarcinoma
@en
Second-line systemic treatment for advanced cholangiocarcinoma
@nl
type
label
Second-line systemic treatment for advanced cholangiocarcinoma
@ast
Second-line systemic treatment for advanced cholangiocarcinoma
@en
Second-line systemic treatment for advanced cholangiocarcinoma
@nl
prefLabel
Second-line systemic treatment for advanced cholangiocarcinoma
@ast
Second-line systemic treatment for advanced cholangiocarcinoma
@en
Second-line systemic treatment for advanced cholangiocarcinoma
@nl
P2093
P2860
P1476
Second-line systemic treatment for advanced cholangiocarcinoma
@en
P2093
Ahmed Kaseb
Jane E Rogers
Lindsey Law
Milind M Javle
Rachna T Shroff
Van D Nguyen
P2860
P304
P356
10.3978/J.ISSN.2078-6891.2014.072
P577
2014-12-01T00:00:00Z